Spinocerebellar Ataxia Type 3 Clinical Trial
Official title:
A Randomised Controlled Trial on the Clinical Efficacy of Oral Trehalose in Patients With Spinocerebellar Ataxia 3: Clinical & FMRI Correlation
This study evaluates the effectiveness of oral trehalose in alleviating the neuropathological and motor behaviour deficits among patients with SCA3. A total of 40 participants with SCA3 will be recruited, with 20 participants to be administered with trehalose while another 20 participants to be administered with a maltose placebo.
Status | Recruiting |
Enrollment | 20 |
Est. completion date | June 30, 2023 |
Est. primary completion date | May 30, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 85 Years |
Eligibility | Inclusion Criteria: - Age between 18 and 85 years old. - Genetically confirmed SCA 3 diagnosis. - Presence of progressive cerebellar syndrome (i.e. symptomatic) and genetic confirmation of SCA 3 in one of the immediate family members with similar clinical syndrome. - Able to read, speak, and understand English or Malay. Exclusion Criteria: - Diagnosis of Diabetes Mellitus Type 1 or Type 2 - Presence of any concomitant neurological condition that might interfere with clinical measures used in this study. - Presence of contraindication or hypersensitivity to trehalose. - Use of stimulant / medication, caffeine, and tobacco within less than 24 hours washout period prior to assessment and / or scan. - Presence of severe visual and / or auditory perceptual deficits. - MRI contra-indications: claustrophobia, pregnancy, electronic implants (e.g. pacemaker) in the body, aneurysm clip, and current or past employment as machinists, welders or metal workers. |
Country | Name | City | State |
---|---|---|---|
Malaysia | UKM Medical Centre | Cheras | Kuala Lumpur |
Lead Sponsor | Collaborator |
---|---|
National University of Malaysia | Radboud University Medical Center |
Malaysia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Changes from Baseline Structural / T1 MRI at 3 months. | The level of measurement of grey matter density (structural) is continuous; greater grey matter density indicates greater structural volume. | Baseline and 3 months | |
Other | Changes from Baseline Situational Motivation Scale (SIMS) at 3 months and 6 months; as well as 3, 6, 9, and 12 months post-treatment follow-up. | SIMS comprises 16 items on four subscales, Intrinsic motivation (e.g., "I think that this activity is interesting"), Identified regulation (e.g., "I am doing it for my own good"), External regulation (e.g., "I am supposed to do it") and Amotivation (e.g., "I don't see what this activity brings me"). It contains 4 items per subscale scored on a scale from 1 to 7 providing a score between 4 and 28 for each subscale. It has an internal reliability of a = .74 - .83 for the four subscales. Total time taken for test administration is estimated at 5 minutes. | Baseline, 3 months, and 6 months; as well as 3, 6, 9, and 12 months post-treatment follow-up. | |
Other | Changes from Baseline EuroQol-5D 3L (EQ-5D-3L) at 3 months and 6 months; as well as 3, 6, 9, and 12 months post-treatment follow-up. | EQ-5D-3L consists of 2 parts: the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). EQ-5D has 5 dimensions of assessment (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). Each dimension has 3 levels (ordinal): no problem, some problem, and extreme problem. It has an internal reliability of a = .83 and valid among clinically and demographically heterogeneous patients. Total time taken for test administration is estimated at 5 minutes. | Baseline, 3 months, and 6 months; as well as 3, 6, 9, and 12 months post-treatment follow-up. | |
Other | Adverse event | Adverse event will be recorded in terms of severity, study intervention relationship, action taken regarding study intervention, outcome of adverse event, expected, and serious adverse event. | Baseline, 3 months, and 6 months; as well as 3, 6, 9, and 12 months post-treatment follow-up. | |
Primary | Changes from Baseline Scale for Ataxia Rating Assessment (SARA) at 3 months, 6 months; as well as 3, 6, 9, and 12 months post-treatment follow-up. | An 8-item scale to quantify the severity of ataxia with a scoring of 0 (no ataxia) to 40 (most severe ataxia). Total time taken for test administration is estimated at 10 minutes. | Baseline, 3 months, and 6 months, as well as 3, 6, 9, and 12 months post-treatment follow-up. | |
Secondary | Changes from Baseline Spinocerebellar Ataxia Functional Index (SCAFI) at 3 months and 6 months; as well as 3, 6, 9, and 12 months post-treatment follow-up. | A validated multi-modal assessment tool that is composed of: a) timed 8 metre walk (8MW); b) the 9-hole peg test (9HPT); and c) the rate of "PATA" repetition over 10 seconds (PATA) to rate speech performance. Total time taken for test administration is estimated at 10 minutes. | Baseline, 3 months, and 6 months, as well as 3, 6, 9, and 12 months post-treatment follow-up. | |
Secondary | Changes from Baseline Inventory of Non-Ataxia Symptoms (INAS) at 3 months and 6 months; as well as 3, 6, 9, and 12 months post-treatment follow-up. | A validated scale assessing non-cerebellar signs with a scoring of 0 (no non-ataxia sign) to 16 (all assessed systems affected). Total time taken for test administration is estimated at 10 minutes. | Baseline, 3 months, and 6 months; as well as 3, 6, 9, and 12 months post-treatment follow-up. | |
Secondary | Changes from Baseline Cerebellar Cognitive & Affective Syndrome (CCAS) Scale at 3 months and 6 months; as well as 3, 6, 9, and 12 months post-treatment follow-up. | CCAS Scale is a brief cognitive screening tool to help identify CCAS in patients with cerebellar impairment. It derives a total score of 120 as a continuous measure; as well as an ordinal measure in accordance to the number of failed tests: 1) Possible CCAS = 1 failed test; 2) Probable CCAS = 2 failed tests; Definite CCAS = 3 or more failed tests. Four different forms were available to minimize the practice effect. Total time taken for test administration is estimated at 10 minutes. | Baseline, 3 months, and 6 months; as well as 3, 6, 9, and 12 months post-treatment follow-up. | |
Secondary | Changes from Baseline Wechsler Adult Intelligence Scale (WAIS - 4) at 3 months and 6 months; as well as 3, 6, 9, and 12 months post-treatment follow-up. | WAIS - 4 is an IQ test designed to measure intelligence and cognitive ability in adults and older adolescents. The selected subtests are Matrix Reasoning, Digit Span, and Coding. These subtests are used to measure abstract reasoning, WM, and processing speed respectively. These index and subtests have good reliability | Baseline, 3 months, and 6 months; as well as 3, 6, 9, and 12 months post-treatment follow-up. | |
Secondary | Changes from Baseline Delis-Kaplan Executive Function System (D - KEFS) at 3 months and 6 months; as well as 3, 6, 9, and 12 months post-treatment follow-up. | D - KEFS is a neuropsychological battery designed to measure various subdomains of executive function from 8 - 89 years old. The selected subtests are: Tower Test, Trail Making Test (TMT), Colour-Word Interference Test (CWIT). These tests measure planning, set-shifting, and inhibition abilities respectively. | Baseline, 3 months, and 6 months; as well as 3, 6, 9, and 12 months post-treatment follow-up. | |
Secondary | Changes from Baseline Repeatable Battery for the Assessment of Neuropsychological Status Update (RBANS Update) at 3 months and 6 months; as well as 3, 6, 9, and 12 months post-treatment follow-up. | RBANS Update is a neuropsychological battery designed to measure 5 neuropsychological domains from 12:0 - 89:11 years old. The selected subtests are: Figure Copy and Figure Recall. These tests measure visual construction, visual memory, and language abilities respectively. | Baseline, 3 months, and 6 months; as well as 3, 6, 9, and 12 months post-treatment follow-up. | |
Secondary | Changes from Baseline Resting state fMRI at 3 months. | The level of measurement of oxy-Hb (activation level) is continuous; greater oxy-Hb (mM.mm) indicates greater activation. | Baseline and 3 months | |
Secondary | Changes from Magnetic resonance spectroscopy at 3 months. | The level of measurement of N-Acetyl Aspartate (NAA; metabolism) is continuous; greater NAA (ppm) indicates greater metabolism. | Baseline and 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00992771 -
Study to Determine the Safety and Tolerability of Varenicline (Chantix®) in Treating Spinocerebellar Ataxia Type 3
|
Phase 2 | |
Completed |
NCT01096082 -
Safety and Efficacy of Lithium Carbonate in Patients With Spinocerebellar Ataxia Type 3
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT03701399 -
Troriluzole in Adult Subjects With Spinocerebellar Ataxia
|
Phase 3 | |
Active, not recruiting |
NCT04229823 -
Natural History of Oculomotor Neurophysiology in Ataxic and Pre-ataxic Carriers of SCA3/MJD
|
||
Active, not recruiting |
NCT04419974 -
Astrocytic Markers and the Pre-ataxic Period of SCA3/MJD - BIGPRO Study Astrocytes
|
||
Terminated |
NCT05490563 -
STRIDES - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia
|
Phase 2/Phase 3 | |
Withdrawn |
NCT04301284 -
Study of CAD-1883 for Spinocerebellar Ataxia
|
Phase 2 | |
Withdrawn |
NCT01096095 -
Pilot Study of Safety and Efficacy of Sodium Phenylbutyrate in Spinocerebellar Ataxia Type 3
|
Phase 2 | |
Active, not recruiting |
NCT04268147 -
Instrumented Data Exchange for Ataxia Study
|
||
Recruiting |
NCT01793168 -
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
|
||
Active, not recruiting |
NCT05826171 -
Priming Motor Learning Through Exercise in People With Spinocerebellar Ataxia
|
N/A | |
Completed |
NCT03885167 -
Identification of Biomarkers in Spinocerebellar Ataxia 3
|
||
Terminated |
NCT05160558 -
A Pharmacokinetics and Safety Study of BIIB132 in Adults With Spinocerebellar Ataxia 3
|
Phase 1 | |
Recruiting |
NCT05822908 -
A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT03378414 -
Umbilical Cord Mesenchymal Stem Cells Therapy (19#iSCLife®-SA) for Patients With Spinocerebellar Ataxia
|
Phase 2 | |
Completed |
NCT05502432 -
Repetitive Transcranial Magnetic Stimulation in SCA3 Patients
|
N/A | |
Recruiting |
NCT04714307 -
Neuropsychiatry and Cognition in SCA3/MJD
|
||
Recruiting |
NCT05557786 -
Treatment of Transcranial Alternating Current Stimulation(tACS)on Cerebellar Ataxia
|
||
Recruiting |
NCT01060371 -
Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias
|